Roche Holding AG (SWX:ROG)
245.50
-0.80 (-0.32%)
Aug 12, 2025, 5:01 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B
Revenue Growth
+4.80%
P/S Ratio
3.33
Revenue / Employee
614.90K
Employees
103,249
Market Cap
211.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Alcon | 8.77B |
Galderma Group AG | 3.73B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Roche Holding AG News
- 23 hours ago - Roche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: Reuters - Seeking Alpha
- 1 day ago - Swiss government to meet pharma firms to discuss US tariffs - Reuters
- 2 days ago - Swiss Government Engages Roche and Novartis on U.S. Tariff Impact - GuruFocus
- 7 days ago - Roche gets FDA clearance for respiratory test to detect viruses - Seeking Alpha
- 10 days ago - Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD) - GlobeNewsWire
- 10 days ago - Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD) - Business Wire
- 13 days ago - Trump's pharmaceutical tariffs could affect some drugmakers more than others - CNBC
- 14 days ago - U.S. and European Union trade deal could cost the pharma industry up to $19 billion - Fast Company